{
  "guideline": {
    "id": "PA166211021",
    "name": "Annotation of DPWG Guideline for siponimod and CYP2C9",
    "source": "DPWG",
    "version": 7,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166211021",
    "relatedChemicals": [
      {
        "id": "PA166182736",
        "name": "siponimod",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451445241,
            "_label": "*1",
            "function": {
              "term": "Normal function (CYP2C9*1)",
              "termId": "alleleFunction:1451444660"
            }
          },
          {
            "id": 1451445242,
            "_label": "*2",
            "function": {
              "term": "Decreased function (CYP2C9*2)",
              "termId": "alleleFunction:1451444630"
            }
          },
          {
            "id": 1451445243,
            "_label": "*3",
            "function": {
              "term": "Decreased function (CYP2C9*3)",
              "termId": "alleleFunction:1451444680"
            }
          },
          {
            "id": 1451445266,
            "_label": "*4",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445267,
            "_label": "*5",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445268,
            "_label": "*6",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          },
          {
            "id": 1451445269,
            "_label": "*8",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445270,
            "_label": "*11",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445271,
            "_label": "*12",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445301,
            "_label": "*13",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA504",
            "name": "chr10",
            "symbol": null
          },
          "strand": "plus",
          "id": "PA126",
          "name": "cytochrome P450 family 2 subfamily C member 9",
          "symbol": "CYP2C9"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166243962",
      "name": "*1/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451445306,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445308,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": {
        "id": 1451445305,
        "html": "<p>The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243942",
      "name": "Normal Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Normal function (CYP2C9*1)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451445248,
        "html": "<p>Normal Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445249,
        "html": "<p>The guideline does not provide a recommendation for siponimod in normal metabolizers.</p>\n"
      },
      "implications": {
        "id": 1451445247,
        "html": "<p>The guideline does not provide a description of the impact of a normal metabolizer phenotype on siponimod.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243981",
      "name": "*2/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*2)"
      ],
      "metabolizerStatus": {
        "id": 1451445321,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445323,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": {
        "id": 1451445320,
        "html": "<p>The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243941",
      "name": "Intermediate Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function/Normal function (CYP2C9*1)",
        "CYP2C9:No function/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838427,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838428,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For the comparable genetic variation *1/*3, the moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": {
        "id": 1451838426,
        "html": "<p>Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243961",
      "name": "Poor Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/No function",
        "CYP2C9:Decreased function (CYP2C9*3)/No function",
        "CYP2C9:Decreased function/Decreased function",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*2)",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*3)",
        "CYP2C9:Decreased function/No function",
        "CYP2C9:No function/No function"
      ],
      "metabolizerStatus": {
        "id": 1451838391,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838392,
        "html": "<p>Avoid siponimod.</p>\n"
      },
      "implications": {
        "id": 1451838390,
        "html": "<p>Siponimod is contraindicated in patients with the comparable genetic variation *3/*3. Theoretically, the risk of adverse effects is greatly increased, as the genetic variation results in much higher plasma concentrations of siponimod.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243963",
      "name": "*1/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838441,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838443,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": {
        "id": 1451838440,
        "html": "<p>Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243982",
      "name": "*2/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838430,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838432,
        "html": "<p>Use 50% of the normal maintenance dose. Reconsider the choice and the potential benefit of siponimod if the patient is also using a moderate CYP3A4 inducer, such as modafinil. For this genetic variation, a moderate CYP3A4 inducer results in a reduction in the exposure of siponimod by 49%, according to a pharmacokinetic model.</p>\n"
      },
      "implications": {
        "id": 1451838429,
        "html": "<p>Theoretically, the risk of adverse effects in increased, as the genetic variation results in higher plasma concentrations of siponimod.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244001",
      "name": "*3/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838409,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838411,
        "html": "<p>Avoid siponimod.</p>\n"
      },
      "implications": {
        "id": 1451838408,
        "html": "<p>Siponimod is contraindicated in patients with this genetic variation. Theoretically, the risk of adverse effects is greatly increased, as the genetic variation results in much higher plasma concentrations of siponimod.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [],
  "version": "2023-04-05-11-38"
}